EP1572103A4 - Utilisations anti-angiogeniques d'antagonistes de il-6 - Google Patents

Utilisations anti-angiogeniques d'antagonistes de il-6

Info

Publication number
EP1572103A4
EP1572103A4 EP03783264A EP03783264A EP1572103A4 EP 1572103 A4 EP1572103 A4 EP 1572103A4 EP 03783264 A EP03783264 A EP 03783264A EP 03783264 A EP03783264 A EP 03783264A EP 1572103 A4 EP1572103 A4 EP 1572103A4
Authority
EP
European Patent Office
Prior art keywords
angiogenic
antagonists
angiogenic uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783264A
Other languages
German (de)
English (en)
Other versions
EP1572103A2 (fr
Inventor
Mohit Trikha
Zhao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1572103A2 publication Critical patent/EP1572103A2/fr
Publication of EP1572103A4 publication Critical patent/EP1572103A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP03783264A 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6 Withdrawn EP1572103A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42690102P 2002-11-15 2002-11-15
US426901P 2002-11-15
PCT/US2003/035651 WO2004045507A2 (fr) 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6

Publications (2)

Publication Number Publication Date
EP1572103A2 EP1572103A2 (fr) 2005-09-14
EP1572103A4 true EP1572103A4 (fr) 2008-02-13

Family

ID=32326451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783264A Withdrawn EP1572103A4 (fr) 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6

Country Status (5)

Country Link
EP (1) EP1572103A4 (fr)
JP (1) JP2006516957A (fr)
AU (1) AU2003290682A1 (fr)
CA (1) CA2506230A1 (fr)
WO (1) WO2004045507A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
CN101330930B (zh) 2005-10-21 2011-11-23 中外制药株式会社 心脏病治疗剂
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2006332216A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6Ralpha to gp130
CN104189907A (zh) * 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
MX2009001110A (es) 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
TW200936160A (en) * 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010133087A1 (fr) * 2009-05-18 2010-11-25 The University Of Hong Kong Compositions et procédés pour traiter une arthrite inflammatoire
US20120183539A1 (en) * 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
RU2670943C9 (ru) 2012-11-08 2018-11-26 Илэвэн Байотерапьютикс, Инк. Антагонисты ил-6 и их применение
EP2898896A1 (fr) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents pour utilisation dans le traitement de l'inflammation de la rétine
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
RS59805B1 (sr) * 2014-11-07 2020-02-28 Sesen Bio Inc Unapređena il-6 antitela
US11203636B2 (en) 2017-02-01 2021-12-21 Yale University Treatment of existing left ventricular heart failure
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
KR20230047223A (ko) 2018-01-05 2023-04-06 노보 노르디스크 에이/에스 면역억제 없이 il-6 매개 염증을 치료하기 위한 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (fr) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reduction de la fibrose et/ou de la cicatrisation par inhibition de l'activite induite par le recepteur de l'interleukine 6
WO2000078815A1 (fr) * 1999-06-24 2000-12-28 Applied Molecular Evolution Anticorps humains recombinants anti-alphavbeta3, acides nucleiques codant ces anticorps et methodes d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020728A1 (fr) * 1994-12-29 1996-07-11 Chugai Seiyaku Kabushiki Kaisha Potentialisateur d'agent antitumoral comprenant un antagoniste de l'interleukine 6

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (fr) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reduction de la fibrose et/ou de la cicatrisation par inhibition de l'activite induite par le recepteur de l'interleukine 6
WO2000078815A1 (fr) * 1999-06-24 2000-12-28 Applied Molecular Evolution Anticorps humains recombinants anti-alphavbeta3, acides nucleiques codant ces anticorps et methodes d'utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. WENDLING ET AL.: "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.", JOURNAL OF RHEUMATOLOGY, vol. 20, February 1993 (1993-02-01), pages 259 - 262, XP000972960 *
H. VAN ZAANEN ET AL.: "Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, 1998, pages 783 - 790, XP002986057 *
J-Y. BLAY ET AL.: "Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.", INTERNATIONAL JOURNAL OF CANCER, vol. 72, 1997, pages 424 - 430, XP002461200 *
K. YOSHIZAKI ET AL.: "Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.", SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 20, 1998, pages 247 - 259, XP001069950 *
P. SMITH ET AL.: "Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.", PROSTATE, vol. 48, 2001, pages 47 - 53, XP003012696 *

Also Published As

Publication number Publication date
WO2004045507A2 (fr) 2004-06-03
WO2004045507A3 (fr) 2006-01-26
AU2003290682A1 (en) 2004-06-15
JP2006516957A (ja) 2006-07-13
EP1572103A2 (fr) 2005-09-14
CA2506230A1 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
EP1572103A4 (fr) Utilisations anti-angiogeniques d'antagonistes de il-6
IL165841A0 (en) Mchir antagonists
GB0404124D0 (en) Antagonists of GIP
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
PL378134A1 (pl) Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
IL175084A0 (en) Antagonists of the bradykinin b1 receptor
IL181720A0 (en) Bicyclic amides as kinase inhibitors
HK1083096A1 (en) Casr antagonist casr
HK1099021A1 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
PL376509A1 (en) Antagonists il-15
AU2003291959A8 (en) Novel glucagon antagonists
IL163939A0 (en) Nk1 antagonists
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
IL165727A0 (en) Chemokine antagonists
AU2003260072A8 (en) Antagonists of chemokine receptors
ZA200700650B (en) Bicyclic amides as kinase inhibitors
GB2402141B (en) Building block
IL175151A0 (en) Bicyclic pyrazolone cytokine inhibitors
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
GB0327369D0 (en) Scaffolding
GB2389594B (en) Building component
GB2397612B (en) Scaffolding
AU2003264036A8 (en) Pi3k antagonists as radiosensitizers
GB0317503D0 (en) Building components
GB2387610B (en) Building component

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060405BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/00 20060101ALI20071218BHEP

Ipc: A61P 35/04 20060101ALI20071218BHEP

Ipc: A61P 35/00 20060101ALI20071218BHEP

Ipc: A61K 39/395 20060101AFI20060405BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080111

17Q First examination report despatched

Effective date: 20080806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081217